Synonym |
Thai / English name |
Part Used : ผลActivity : DRUG INTERACTIONSolvent/Active Compound : Phyllanthus emblica extractType of experiment : humanType of animal : -Type of study : Open trialN(Total) : 10* (M/F = 6/4)N(Treatment) : 10 (M/F = 6/4)Sex : Both sexAge : 58.60+/-10.54 yrs.Route : Oral administrationDose/Conc.(herb) : single dose of 500 mg Phyllanthus emblica extract + 75 mg ecosprinDuration : -Type of interaction : PharmacodynamicsInteraction with drug : Aspirin*/Acetylsalicylic acid/ASA/EcosprinDose/Conc.(drug) : -Result : PositiveRemark : Result: Combination therapy produced a significant decrease of platelet aggregation after 4 h of treatment, compared to baseline. The percentage inhibition with the combination of P. emblica + ecosprin was 49.25%.Note : *Subject total: Subjects were type II diabetic patients. Conclusion: P. emblica extract demonstrated significant antiplatelet activity with both single and multiple dose administration.
Part Used : ผลActivity : DRUG INTERACTIONSolvent/Active Compound : Phyllanthus emblica extractType of experiment : humanType of animal : -Type of study : Cross overN(Total) : 10* (M/F = 6/4)N(Treatment) : 10 (M/F = 6/4)Sex : Both sexAge : 58.60+/-10.54 yrs.Route : Oral administrationDose/Conc.(herb) : single dose of 500 mg Phyllanthus emblica extract + 75 mg ecosprinDuration : -Type of interaction : PharmacodynamicsInteraction with drug : Aspirin*/Acetylsalicylic acid/ASA/EcosprinDose/Conc.(drug) : -Result : PositiveRemark : Result: Combination therapy produced a significant decrease of platelet aggregation after 4 h of treatment, compared to baseline. The percentage inhibition with the combination of P. emblica + ecosprin was 49.25%.Note : *Subject total: Subjects were type II diabetic patients. Conclusion: P. emblica extract demonstrated significant antiplatelet activity with both single and multiple dose administration.
Part Used : ผลActivity : DRUG INTERACTIONSolvent/Active Compound : Phyllanthus emblica extractType of experiment : humanType of animal : -Type of study : Open trialN(Total) : 10* (M/F = 6/4)N(Treatment) : 10 (M/F = 6/4)Sex : Both sexAge : 58.60+/-10.54 yrs.Route : Oral administrationDose/Conc.(herb) : 500 mg P. emblica extract twice daily + 75 mg ecosprin once dailyDuration : 10 days.Type of interaction : PharmacodynamicsInteraction with drug : Aspirin*/Acetylsalicylic acid/ASA/EcosprinDose/Conc.(drug) : -Result : PositiveRemark : Result: Combination therapy produced a significant decrease of platelet aggregation after 4 h of treatment, compared to basline. The percentage inhibition with the combination of P. emblica + ecosprin was 49.25%. The mean percent inhibition of platelet aggregation on multiple dose administration with combination P. emblica + ecosprin 75 mg was 56.65%. There was statistically significant change observed when combination treatments were compared to P. emblica alone. Though there was apparent increase in inhibition of platelet aggregation with P. emblica + ecosprin Vs. ecosprin alone, this difference was not however statistically significant.Note : *Subject total: Subjects were type II diabetic patients. Conclusion: P. emblica extract demonstrated significant antiplatelet activity with both single and multiple dose administration.
Part Used : ผลActivity : DRUG INTERACTIONSolvent/Active Compound : Phyllanthus emblica extractType of experiment : humanType of animal : -Type of study : Cross overN(Total) : 10* (M/F = 6/4)N(Treatment) : 10 (M/F = 6/4)Sex : Both sexAge : 58.60+/-10.54 yrs.Route : Oral administrationDose/Conc.(herb) : 500 mg P. emblica extract twice daily + 75 mg ecosprin once dailyDuration : 10 days.Type of interaction : PharmacodynamicsInteraction with drug : Aspirin*/Acetylsalicylic acid/ASA/EcosprinDose/Conc.(drug) : -Result : PositiveRemark : Result: Combination therapy produced a significant decrease of platelet aggregation after 4 h of treatment, compared to basline. The percentage inhibition with the combination of P. emblica + ecosprin was 49.25%. The mean percent inhibition of platelet aggregation on multiple dose administration with combination P. emblica + ecosprin 75 mg was 56.65%. There was statistically significant change observed when combination treatments were compared to P. emblica alone. Though there was apparent increase in inhibition of platelet aggregation with P. emblica + ecosprin Vs. ecosprin alone, this difference was not however statistically significant.Note : *Subject total: Subjects were type II diabetic patients. Conclusion: P. emblica extract demonstrated significant antiplatelet activity with both single and multiple dose administration.